Integrative Analyses Identify KCNJ15 as a Candidate Gene in Patients with Epilepsy

Shorvon SD. Epidemiology, classification, natural history, and genetics of epilepsy. Lancet. 1990;336:93–6.

Brodie MJ, Barry SJE, Bamagous GA, Norrie JD, Kwan P. Patterns of treatment response in newly diagnosed epilepsy. Neurology. 2012;78:1548–54.

Picot MC, Baldy-Moulinier M, Daurès JP, Dujols P, Crespel A. The prevalence of epilepsy and pharmacoresistant epilepsy in adults: a population-based study in a Western European country. Epilepsia. 2008;49:1230–8.

Fisher RS, Vickrey BG, Gibson P, et al. The impact of epilepsy from the patient’s perspective II: views about therapy and health care. Epilepsy Res. 2000;41:53–61.

Eddy CM, Rickards HE, Cavanna AE. The cognitive impact of antiepileptic drugs. Ther Adv Neurol Disorder. 2011;4:385–407.

Duncan JS, Sander JW, Sisodiya SM, Walker MC. Adult epilepsy. Lancet. 2006;367:1087–100.

Perry MS, Duchowny M. Surgical versus medical treatment for refractory epilepsy: outcomes beyond seizure control. Epilepsia. 2013;54:2060–70.

Kullmann DM, Schorge S, Walker MC, Wykes RC. Gene therapy in epilepsy–is it time for clinical trials? Nat Rev Neurol. 2014;10:300–4.

Nikitin ES, Vinogradova LV. Potassium channels as prominent targets and tools for the treatment of epilepsy. Expert Opin Ther Targets. 2021;25:223–35.

Uhlén M, Fagerberg L, Hallström BM, et al. Proteomics: tissue-based map of the human proteome. Science. 2015;347:1260419.

Nakajima KI, Zhu K, Sun YH, et al. KCNJ15/Kir4.2 couples with polyamines to sense weak extracellular electric fields in galvanotaxis. Nat Commun. 2015;6:8532.

Bentley SR, Guella I, Sherman HE, et al. Hunting for familial Parkinson’s disease mutations in the post genome era. Genes (Basel). 2021;12:430.

Zhou X, Chen Y, Mok KY, et al. Identification of genetic risk factors in the Chinese population implicates a role of immune system in Alzheimer’s disease pathogenesis. Proc Natl Acad Sci USA. 2018;115:1697–706.

International League Against Epilepsy Consortium on Complex Epilepsies. Genome-wide mega-analysis identifies 16 loci and highlights diverse biological mechanisms in the common epilepsies. Nat Commun. 2018;9:5269.

Wishart DS, Feunang YD, Guo AC, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46:D1074–82.

Wang Y, Zhang S, Li F, et al. Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics. Nucleic Acids Res. 2020;48:D1031–41.

von Mering C, Huynen M, Jaeggi D, Schmidt S, Bork P, Snel B. STRING: a database of predicted functional associations between proteins. Nucleic Acids Res. 2003;31:258–61.

Su G, Morris JH, Demchak B, Bader GD. Biological network exploration with Cytoscape 3. Curr Protoc Bioinform. 2014;47:1–24.

Wang S, Zhou L, He C, et al. The association between STX1B polymorphisms and treatment response in patients with epilepsy. Front Pharmacol. 2021;12: 701575.

Wu SY, Chen YW, Tsai SF, et al. Estrogen ameliorates microglial activation by inhibiting the Kir2.1 inward-rectififier K(+) channel. Sci Rep. 2016;6:22864.

Di Lucente J, Nguyen HM, Wulff H, Jin LW, Maezawa I. The voltage-gated potassium channel Kv1.3 is required for microglial pro-inflammatory activation in vivo. Glia. 2018;66:1881–95.

Wyatt-Johnson SK, Brewster AL. Emerging roles for phagocytic microglial signaling in epilepsy. Epilepsy Curr. 2020;20:33–8.

Zhao XF, Liao Y, Alam MM, et al. Microglial mTOR is neuronal protective and antiepileptogenic in the pilocarpine model of temporal lobe epilepsy. J Neurosci. 2020;40:7593–608.

Devinsky O, Vezzani A, Najjar S, De Lanerolle NC, Rogawski MA. Glia and epilepsy: excitability and inflammation. Trends Neurosci. 2013;36:174–84.

Heinzen EL, Yoon W, Weale ME, et al. Alternative ion channel splicing in mesial temporal lobe epilepsy and Alzheimer’s disease. Genome Biol. 2007;8:R32.

Wang S, Zhang X, Zhou L, Wu Q, Han Y. Analysis of GABRG2 C588T polymorphism in genetic epilepsy and evaluation of GABRG2 in drug treatment. Clin Transl Sci. 2021;00:1–9.

van Dam S, Võsa U, van der Graaf A, Franke L, de Magalhães JP. Gene co-expression analysis for functional classification and gene–disease predictions. Brief Bioinform. 2018;19:575–92.

Goh KI, Cusick ME, Valle D, Childs B, Vidal M, Barabási AL. The human disease network. Proc Natl Acad Sci USA. 2007;104:8685–90.

Lage K, Hansen NT, Karlberg EO, et al. A large-scale analysis of tissue-specific pathology and gene expression of human disease genes and complexes. Proc Natl Acad Sci USA. 2008;105:20870–5.

Zhao M, Zhang T, Li G, Qiu F, Sun Y, Zhao L. Associations of CYP2C9 and CYP2A6 polymorphisms with the concentrations of valproate and its hepatotoxin metabolites and valproate-induced hepatotoxicity. Basic Clin Pharmacol Toxicol. 2017;121:138–43.

Yoon HY, Ahn MH, Yee J, Lee N, Han JM, Gwak HS. Influence of CYP2C9 and CYP2A6 on plasma concentrations of valproic acid: a meta-analysis. Eur J Clin Pharmacol. 2020;76:1053–8.

Chakraborty C, Doss CGP, Chen L, Zhu H. Evaluating protein-protein interaction (PPI) networks for diseases pathway, target discovery, and drug-design using ‘in silico pharmacology.’ Curr Protein Pept Sci. 2014;15:561–71.